Stradling J R, Davies R J
University of Oxford and Osler Chest Unit, Churchill Hospital, UK.
Sleep. 2000 Jun 15;23 Suppl 4:S150-3.
To assess the benefit of NCPAP in OSA and its relation to the degree of use of NCPAP.
Randomised parallel controlled one month study comparing NCPAP set at therapeutic levels of pressure, with NCPAP set at sub-therapeutic pressure levels.
Teaching hospital sleep clinic and laboratory
101 men referred for investigation of possible OSA who were sleepy (Epworth Sleepiness Score > or = 10) and had > or = 10/hr of >4% dips in SaO2 due to OSA.
Baseline and one month measures of Epworth Sleepiness Score (ESS), Maintenance of Wakefulness Test (MWT), and the Energy/Vitality dimension of the SF-36 (health status questionnaire). Correlation of these outcome measures with NCPAP usage.
All outcome measures improved significantly more in the therapeutic, compared to the sub-therapeutic, group (e.g. ESS 15.0 to 13.0 on sub-therapeutic, and 15.5 to 7.0 on therapeutic, p<1x10(-6)). The degree of improvement correlated significantly with NCPAP usage in the therapeutic group (ESS, r=-0.60; MWT, r=0.55) but insignificantly in the sub-therapeutic group (ESS, r=-0.15; MWT, r=-0.06). Sub-therapeutic NCPAP did not improve OSA severity and acted as a control.
NCPAP is clearly effective in relieving the sleepiness of OSA compared to a control group identical in every way, except for receiving a nasal pressure inadequate to control the OSA.
评估持续气道正压通气(NCPAP)治疗阻塞性睡眠呼吸暂停(OSA)的益处及其与NCPAP使用程度的关系。
随机平行对照的为期1个月的研究,比较设置在治疗压力水平的NCPAP与设置在亚治疗压力水平的NCPAP。
教学医院睡眠诊所和实验室
101名因可能患有OSA而被转诊进行检查的男性,这些男性有嗜睡症状(爱泼沃斯嗜睡量表评分≥10分),且因OSA导致血氧饱和度(SaO2)每小时下降≥10次且降幅>4%。
爱泼沃斯嗜睡量表评分(ESS)、清醒维持试验(MWT)的基线和1个月测量值,以及健康状况调查问卷SF-36的精力/活力维度。这些观察指标与NCPAP使用情况的相关性。
与亚治疗组相比,治疗组的所有观察指标改善更为显著(例如,亚治疗组的ESS从15.0降至13.0,治疗组从15.5降至7.0,p<1×10⁻⁶)。治疗组中改善程度与NCPAP使用情况显著相关(ESS,r=-0.60;MWT,r=0.55),而亚治疗组中相关性不显著(ESS,r=-0.15;MWT,r=-0.06)。亚治疗水平的NCPAP并未改善OSA严重程度,起到了对照作用。
与除接受不足以控制OSA的鼻压力外其他方面均相同的对照组相比,NCPAP在缓解OSA导致的嗜睡方面显然有效。